Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3674-3690

  Bradshaw, Donna M ^a   Arceci, Robert J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXNIGULDIPINE; DEXVERAPAMIL; DILTIAZEM; DOXORUBICIN; EPIPODOPHYLLOTOXIN; GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; CANCER CELL; CYTOTOXICITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0031764330     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3674     Document Type: Review

References (240)

1. Filipits M, Suchomel RW, Zochbauer S, et al: Relevance of drug resistance genes in malignant diseases. Leukemia 10:S10-S17, 1996
2. Arceci R: Tumor survival and resistance to therapy. Curr Opin Hematol 3:279-287, 1996
3. Juliano R, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162, 1976
4. Hype S, Emsley P, Hartshorn M, et al: Structure model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance, and bacterial transport. Nature 346:362-365, 1990
5. Bosch I, Croop J: P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288:F37-F54, 1996
6. Nooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192:768-780, 1996
7. Ling V: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3-S8, 1997
8. Gros P, Ben Neriah YB, Croop JM, et al: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731, 1986
9. Croop JM, Guild BC, Gros P, et al: Genetics of multidrug resistance: Relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer Res 47:5982-5988, 1987
10. Saeki T, Shimabuku AM, Ueda K, et al: Specific drug binding by purified lipid-reconstituted P-glycoprotein: Dependence on the lipid composition. Biochim Biophys Acta 1107:105-110, 1992
11. Thierry AR, Dritschilo A, Rahman A: Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun 187:1098-1105, 1992
12. Sharom FJ, Yu X, Doige CA: Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 268:24197-24202, 1993
13. Naito M, Tsuruo T: Reconstitution of purified P-glycoprotein into liposomes. J Cancer Res Clin Oncol 121:582-586, 1995
14. Shapiro AB, Ling V: Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270:16167-16175, 1995
15. Dong M, Penin F, Baggetto LG: Efficient purification and reconstitution of P-glycoprotein for functional and structural studies. J Biol Chem 271:28875-28883, 1996
16. Eytan GD, Regev R, Oren G, et al: Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248:104-112, 1997
17. de Vree JM, Jacquemin E, Sturm E, et al: Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 95:282-287, 1998
18. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al: Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145:1237-1245, 1994
19. Smit JJ, Schinkel AH, Oude Elferink RP, et al: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462, 1993
20. Oude Elferink RP, Ottenhoff R, van Wijland M, et al: Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 95:31-38, 1995
21. Smit JJ, Baas F, Hoogendijk JE, et al: Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene. J Neurosci 16:6386-6393, 1996
22. Cordon-Cardo C, O'Brien J, Boccia J, et al: Expression of multidrug-resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem 38:1277-1287, 1990
23. Fojo A, Ueda K, Slamon D, et al: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84:265-269, 1987
24. Cordon-Cardo C, O'Brien JP, Casals D, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695-698, 1989
25. Schinkel AH, Smit JJ, van Tellingen O, et al: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502, 1994
26. Schinkel AH, Mayer U, Wagenaar E, et al: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94:4028-4033, 1997
27. Schinkel AH, Mol CA, Wagenaar E, et al: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295-1298, 1995
28. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94, 1991
29. Twentyman PR: Transport proteins in drug resistance: Biology and approaches to circumvention. J Int Med 740:133-137, 1997 (suppl)
30. Marie J: P-Glycoprotein in Adult Hematologic Malignancies. Philadelphia, PA, Saunders, 1995
31. List AF: The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10:S36-S38, 1996
32. Willman CL: The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34:25-33, 1997
33. Nussler V, Pelka-Fleischer R, Zwierna H, et al: P-glycoprotein expression in patients with acute leukemia. Leukemia 10:S23-S31, 1996
34. Leith C, Kopecky K, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329, 1997
35. Chan H, Haddad G, Thorner P: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614, 1991
36. Chan H, Thorner P, Haddad G, et al: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990
37. Beck W, Grogan T, Willman C, et al: Methods to detect P-glycoprotein-associated resistance in patients' tumors: Consensus recommendations. Cancer Res :3010-3020, 1996
38. Luker GD, Fracasso PM, Dobkin J, et al: Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo. J Nucl Med 38:369-372, 1997
39. Vecchio SD, Ciarmiello A, Potena MI, et al: In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Euro J Nucl Med 24:150-159, 1997
40. Kostakoglu L, Elahi N, Kiratli P, et al: Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 38:1003-1008, 1997
41. Barbaries E, Kronauge JF, Cohen D, et al: Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 58:276-282, 1998
42. Fojo A, Whang-peng J, Gottesman M, et al: Amplification of DNA sequences in human multidrug resistant KB carcinoma cells. Proc Natl Acad Sci U S A 82:7661-7665, 1985
43. van der Heyden S, Gheuens E, de Bruijn E, et al: P-glycoprotein: Clinical significance and methods of analysis. Crit Rev Lab Sci 32:221-264, 1995
44. Holmes JA, Whittaker JA, Padua RA: Effect of position 185 mutations of the MDR-1 gene on drug resistance in leukemia. Leukemia 6:484-485, 1992
45. Safa AR, Stern RK, Choi K, et al: Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci U S A 87:7225-7229, 1990
46. Choi KH, Chen CJ, Kriegler M, et al: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53:519-529, 1988
47. Stein U, Walther W, Wunderlich V: Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 10:1541-1545, 1994
48. Kajiji S, Dreslin JA, Grizzuti K, et al: Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine 939/941. Biochemistry 33:5041-5048, 1994
49. Gros P, Dhir R, Croop J, et al: A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 88:7289-7293, 1991
50. Ueda K, Pastan I, Gottesman M: Isolation and sequence of the promoter region of the human multidmg-resistance (P-glycoprotein) gene. J Biol Chem 262:17432-17436, 1987
51. Chin K, Kaimitsu U, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462, 1992
52. Combates NJ, Rzepka RW, Chen YN, et al: NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269:29715-29719, 1994
53. Thorgeirsson S, Huber B, Sorrell S, et al: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236:1120-1102, 1987
54. Marino P, Gottesman M, Pastan I: Regulation of the multidrug-resistance gene in regenerating liver. Cell Growth Differ 2:57-62, 1990
55. Arceci R, Croop J, Horwitz S, et al: The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci U S A 85:4350-4354, 1988
56. Baas F, Jongsma A, Broxterman H, et al: Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50:5392-5398, 1990
57. Shinkel A, Kemp S, Dolle M, et al: N-glycosylation and deletion mutants of the human mdr 1 P-glycoprotein. J Biol Chem 268:7474-7481, 1993
58. Fine R, Chambers T, Sachs C: P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14:47-55, 1996
59. Loe D, Deeley R, Cole S: Biology of the multidrug-resistance-associated protein, MRP. Eur J Cancer 32A:945-957, 1996
60. Cole S, Bhardwaj G, Gerlach J: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650-1654, 1992
61. Lautier D, Canitrot Y, Deeley RG, et al: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967-977, 1996
62. Kool M, de Haas M, Scheffer GL, et al: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug-resistance-associated protein gene (MRP1) in human cancer cell lines. Cancer Res 57:3537-3547, 1997
63. Keppler D, Leier I, Jedlitschky G: Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378:787-791, 1997
64. Breuninger LM, Paul S, Gaughan K, et al: Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55:5342-5347, 1995
65. Kruh GD, Chan A, Myers K, et al: Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 54:1649-1652, 1994
66. Grant CE, Valdimarsson G, Hipfner DR, et al: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994
67. Kuss BJ, Deeley RG, Cole SP, et al: Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: Prognostic implications. Lancet 343:1531-1534, 1994
68. Twentyman P, Rhodes T, Rayner S: A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30A: 1360-1369, 1994
69. Homolya L, Hollo Z, Germann U, et al: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493-21496, 1993
70. Feller N, Broxterman HJ, Wahrer DC, et al: ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion. FEBS Lett 368:385-388, 1995
71. O'Brien M, Tew K: Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A:967-978, 1996
72. Hamilton T, Winker M, Louie K, et al: Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine-mediated glutathione depletion. Biochem Pharmacol 34:2583-2586, 1985
73. Durse L, Mimnaugh E, Myers C, et al: Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multi-drug resistant human breast tumor cells. Cancer Res 49:511-515, 1989
74. Jedlitschky G, Leir I, Bucholz U, et al: ATP-dependent transport of glutathionine-S conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833-4836, 1994
75. Muller M, Meijer C, Zaman G, et al: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathionine-S-conjugate transport. Proc Natl Acad Sci U S A 91:13033-13037, 1994
76. Kuo MT, Bao JJ, Curley SA, et al: Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56:3642-3644, 1996
77. Jedlitschky G, Leier I, Buchholz U, et al: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56:988-994, 1996
78. Paulusma CC, Bosma PJ, Zaman GJ, et al: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-1128, 1996
79. Paulusma CC, Oude Elferink RP: The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 75:420-428, 1997
80. Buchler M, Konig J, Brom M, et al: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091-15098, 1996
81. Paulusma CC, Kool M, Bosma PJ, et al: A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539-1542, 1997
82. Kartenbeck J, Leuschner U, Mayer R, et al: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061-1066, 1996
83. Goto S, Yoshida K, Morikawa T, et al: Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 55:4297-4301, 1995
84. Ishikawa T, Wright C, Ishizuka H: GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL60 cells and downregulated by cell differentiation. J Biol Chem 269:29085-29093, 1994
85. Ishikawa T, Bao JJ, Yamane Y, et al: Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271:14981-14988, 1996
86. 4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Natl Cancer Inst 86:1781-1784, 1994
87. Broxterman H, Giaccone G, Lankelma J: Multidrug resistance protein and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7:532-540, 1995
88. Schneider E, Cowan KH, Bader H, et al: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186-193, 1995
89. Abbaszadegan MR, Futscher BW, Klimecki WT, et al: Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54:4676-4679, 1994
90. Nooter K, Burger H, Stoter G: Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymph 20:381-387, 1996
91. List AF: Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hematol 34:20-24, 1997
92. Burger H, Nooter K, Zaman GJ, et al: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8:990-997, 1994
93. Zhou DC, Zittoun R, Marie JP: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9:1661-1666, 1995
94. Norris MD, Bordow SB, Marshall GM, et al: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. New Engl J Med 334:231-238, 1996
95. Joshi VV, Tsongalis GJ: Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma. Ann N Y Acad Sci 824:71-83, 1997
96. Berger W, Hauptmann E, Elbling L, et al: Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 71:108-115, 1997
97. Elliott T: How does TAP associate with MHC class I molecules? Immunol Today 18:375-379, 1997
98. Simmons WA, Roopenian DC, Summerfield SG, et al: A new MHC locus that influences class I peptide presentation. Immunity 7:641-651, 1997
99. Izquierdo MA, Neefjes JJ, Mathari AE, et al: Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 74:1961-1967, 1996
100. Gromme M, van der Valk R, Sliedregt K, et al: The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur J Immunol 27:898-904, 1997
101. Scheper R, Broxterman H. Scheffer G, et al: Overexpression of a 110-kd vesicular protein in non-P-glycoprotein LRP-related multidrug resistance. Cancer Res 53:1475-1479, 1993
102. Izquierdo M, Scheffer G, Flens M, et al: Major vault protein LRP-related multidrug resistance. Eur J Cancer 32A:979-984, 1996
103. Chugani D, Rome L, Kedersha N: Evidence that vault ribonucleoprotein particles localize to the nuclear core complex. J Cell Sci 106:23-29, 1993
104. Izquierdo M, Scheffer G, Flens M, et al: Expression of the non-P-glycoprotein multidrug resistance-associated protein LRP in normal human tissues and tumors. Am J Pathol 148:877-887, 1996
105. Izquierdo M, Shoemaker R, Flens M, et al: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer 65:230-238, 1996
106. Izquierdo M, Scheffer G, Flens M, et al: Broad distribution of the multidrug resistance-related vault protein LRP in normal human tissues and tumors. Am J Pathol 148:877-887, 1996
107. den Boer ML, Pieters R, Kazemier KM, et al: Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91:2092-2098, 1998
108. List A, Spier C, Grogan T, et al: Overexpression of the major vault transporter lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464-2469, 1996
109. Izquierdo M, van der Zee A, Vermorken J: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230-1237, 1995
110. Linn SC, Pinedo HM, van Ark-Otte J, et al: Expression of drug-resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787-795, 1997
111. Uozaki H, Horiuchi H, Ishida T, et al: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336-2344, 1997
112. Dingemans AM, van Ark-Otte J, van der Valk P, et al: Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 7:625-630, 1996
113. Schuurhuis GJ, Broxterman HJ, de Lange JH, et al: Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 64:857-861, 1991
114. Dietel M, Arps H, Lage H, et al: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50:6100-6106, 1990
115. Dietel M, Seidel A: Morphologic alterations in drug sensitive vs drug resistant cells due to cytostatic application. Cancer Treat Rev 17:3-10, 1990
116. el-Deiry WS: Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79-87, 1997
117. Broxterman HJ, Schuurhuis GJ: Transport proteins in drug resistance: Detection and prognostic significance in acute myeloid leukemia. J Int Med 740:8147-8151, 1997
118. Tsuruo T, Lida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P388 leukemia in vivo through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981
119. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222, 1993
120. Fisher G, Sikic B: Clinical studies with modulators of multidrug resistance, in Fisher G, Sikic B (eds): Hematology/Oncology Clinics of North America. Philadelphia, PA, Saunders, 1995, pp 363-382
121. Sikic BI, Fisher GA, Lum BL, et al: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40:S13-S19, 1997
122. Ford J: Modulators of multidrug resistance: Preclinical studies, in Fisher G, Sikic B (eds): Hematology/Oncology Clinics of North America. Philadelphia, PA, Saunders, 1995, pp 337-361
123. Lum B, Fisher G, Brophy N: Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72:3502-3514, 1993
124. Fisher G, Lum B, Haudorff J, et al: Pharmacologic considerations in the modulation of multidrug resistance. Eur J Cancer 32:1082-1088, 1996
125. Wilson WH, Bates SE, Fojo A, et al: Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol 121:R25-R29, 1995
126. Wilson WH, Bates SE, Fojo A, et al: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13:1995-2004, 1995
127. Sonneveld P, Durie B, Lokhorst H, et al: Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet 340:255-259, 1992
128. Cheson B, Nelson A: Clinical trials with PSC-833. Oncology 11:490-493, 1993
129. Wishart G, Bissett D, Paul J, et al: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12:1771-1777, 1994
130. Solary E, Witz B, Caillot D, et al: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88:1198-1205, 1996
131. List AF, Spier C, Greer J, et al: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660, 1993
132. Bartlett NL, Lum BL, Fisher GA, et al: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842, 1994
133. Erlichman C, Moore M, Thiessen JJ, et al: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837-4842, 1993
134. Yahanda AM, Alder KM, Fisher GA, et al: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624-1634, 1992
135. Dahl G, Grier H, Sikic H, et al: Multidrug resistance (MDR) reversal utilizing mitoxantrone, etoposide and continuous-infusion cyclosporine (MEC) in pediatric ANLL, in Buschner M (ed): Acute Leukemia IV: Prognostic Factors. Berlin, Germany, Springer-Verlag, 1993, pp 738-740
136. Fitzgerald D, Willingham M, Carderelli C, et al: A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci U S A 84:4288-4292, 1987
137. Tsuruo T, Hamada H, Sato S, et al: Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 80:627-631, 1989
138. Mano Y, Suzuki H, Terasaki T, et al: Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: Comparison between in vitro and in vivo disposition. J Pharmacol Exp Ther 283:391-401, 1997
139. Mickisch GH, Pai LH, Siegsmund M, et al: Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug-resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J Urol 149:174-178, 1993
140. Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 89:5824-5828, 1992
141. Rittmann-Grauer LS, Yong MA, Sanders V, et al: Reversal of vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 52:1810-1816, 1992
142. Arceci RJ, Stieglitz K, Bras J, et al: Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res 53:310-317, 1993
143. Hamada H, Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A 83:7785-7789, 1986
144. Mickisch GH, Pai LH, Gottesman MM, et al: Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.Cancer Res 52:4427-4432, 1992
145. Shi T, Wrin J, Reeder J, et al: High-affinity monoclonal antibodies against P-glycoprotein. Clin Immunol Immunopathol 76:44-51, 1995
146. Jurcic J, Scheinberg D, Houghton A: Monoclonal antibody therapy of cancer. Cancer Chemother Biol Res Mod 16:168-198, 1996
147. Bertram J, Palfner K, Killian M, et al: Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6:124-134, 1995
148. Daly C, Coyle S, McBride S, et al: mdr1 ribozyme-mediated reversal of the multidrug resistant phenotype in human lung cell lines. Cytotechnology 19:199-205, 1996
149. Bouffard D, Ohkawa T, Kijima H, et al: Oligonucleotide modulation of multidrug resistance. Eur J Cancer 32A:1010-1018, 1996
150. Scanlon KJ, Ishida H, Kashani-Sabet M: Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A 91:11123-11127, 1994
151. Funato T: Circumventing multidrug resistance in human cancer by anti-ribozyme. Jpn J Clin Med 55:1116-1121, 1997
152. Hampel A: The hairpin ribozyme: Discovery, two-dimensional model, and development for gene therapy. Prog Nucl Acid Res Mol Biol 58:1-39, 1998
153. Jones JT, Sullenger BA: Evaluating and enhancing ribozyme reaction efficiency in mammalian cells. Nature Biotechnol 15:902-905, 1997
154. Gibson SA, Shillitoe EJ: Ribozymes. Their functions and strategies for their use. Mol Biotechnol 7:125-137, 1997
155. Germann UA, Shlyakhter D, Mason VS, et al: Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140, 1997
156. Ruetz S, Brault M, Dalton W, et al: Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. Biochemistry 36:8180-8188, 1997
157. Chen HX, Bamberger U, Heckel A, et al: BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53:1974-1977, 1993
158. List AF, Chakos H, Glinsmann-Gibson B, et al: Reversal of classical and non-πP-glycoprotein (PGP)-mediated multidrug resistance (MDR) by BIBW22. Blood 86:516a, 1995 (abstr)
159. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 51:67-72, 1991
160. Lai GM, Moscow JA, Alvarez MG, et al: Contribution of glutathione and glutathione-dependent enzymes in the reversal of Adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49:688-695, 1991
161. Lai SL, Hwang J, Perng RP, et al: Modulation of cisplatin resistance in acquired-resistant non-small-cell lung cancer cells. Oncol Res 7:31-38, 1995
162. Versantvoort CH, Schuurhuis GJ, Pinedo HM, et al: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68:939-946, 1993
163. Versantvoort CH, Broxterman HJ, Lankelma J, et al: Competitive inhibition by genistein and ATP-dependence of daunorubicin transport in intact MRP overexpressing human small-cell lung cancer cells. Biochem Pharmacol 48:1129-1136, 1994
164. Davey RA, Longhurst TJ, Davey MW, et al: Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 19:275-282, 1995
165. 4 receptor antagonist MK571 specifically modulates MRP-associated multidrug resistance. Biochem Biophys Res Commun 208:345-352, 1995
166. Sikic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34:40-47, 1997
167. Beketic-Oreskovic L, Duran GE, Chen G, et al: Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87:1593-1602, 1995
168. Futscher BW, Foley NE, Gleason-Guzman MC, et al: Verapamil suppresses the emergence of P-glycoprotein-mediated multidrug resistance. Int J Cancer 66:520-525, 1996
169. Sonneveld P, Marie JP, Huisman C, et al: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10:1741-1750, 1996
170. Ozols R, Cunnion R, Klecker R, et al: Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647, 1987
171. Kirk J, Houlbrook S, Stuart NS, et al: Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67:1189-1195, 1993
172. Bissett D, Kerr DJ, Cassidy J, et al: Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168-1171, 1991
173. List AF: Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10:937-942, 1996
174. Archinal-Mattheis A, Rzepka RW, Watanabe T, et al: Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7:603-610, 1995
175. Germann UA, Ford PJ, Shlyakhter D, et al: Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141-155, 1997
176. den Ouden D, van den Heuvel M, Schoester M, et al: In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 10:1930-1936, 1996
177. Dantzig AH, Shepard RL, Cao J, et al: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyl-dibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179, 1996
178. Lehnert M, de Giuli R, Kunke K, et al: Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer 5:862-867, 1996
179. Kisara S, Furusawa S, Murata R, et al: Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Oncol Res 7:191-200, 1995
180. Kim JH, Chung JB, Park IS, et al: Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 34:35-44, 1993
181. Kuhl JS, Sikic BI, Blume KG, et al: Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol 20:1048-1054, 1992
182. Sonneveld P, Durie BG, Lokhorst HM, et al: Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340:255-259, 1992
183. Dalton WS, Crowley JJ, Salmon SS, et al: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75:815-820, 1995
184. Presant CA, Kennedy PS, Wiseman C, et al: Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study. Am J Clin Oncol 9:355-357, 1986
185. Kerr DJ, Graham J, Cummings J, et al: The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother Pharmacol 18:239-342, 1986
186. Cairo MS, Siegel S, Anas N, et al: Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49:1063-1066, 1989
187. Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424, 1989
188. Hendrick AM, Harris AL, Cantwell BM: Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Ann Oncol 2:71-72, 1991
189. Salmon SE, Dalton WS, Grogan TM, et al: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50, 1991
190. Miller TP, Grogan TM, Dalton WS, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1991
191. Miller T, Dahlberg S, Grogan T, et al: Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkin's lymphomas. Anticancer Drugs 5:73a, 1994 (abstr)
192. Ohi Y, Ohmori H, Shirahama T, et al: Intravesical instillation of Adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: Preliminary report of a collaborative study. Cancer Chemother Pharmacol 30:S50-S54, 1992
193. Tsushima T, Ohmori H, Ohi Y, et al: Intravesical instillation chemotherapy of Adriamycin with or without verapamil for the treatment of superficial bladder cancer: The final results of a collaborative randomized trial. Cancer Chemother Pharmacol 35:S69-S75, 1994
194. Mross K, Hamm K, Hossfeld DK: Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 31:369-375, 1993
195. Mross K, Bohn C, Edler L, et al: Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 4:45-50, 1993
196. Millward MJ, Cantwell BM, Munro NC, et al: Oral verapamil with chemotherapy for advanced non-small-cell lung cancer: A randomised study. Br J Cancer 67:1031-1035, 1993
197. Saltz L, Murphy B, Kemeny N, et al: A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer 74:2757-2764, 1994
198. Cowie FJ, Pinkerton CR, Phillips M, et al: Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71:877-881, 1995
199. Dalton WS, Crowley JJ, Salmon SS, et al: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75:815-820, 1995
200. Scheithauer W, Schenk T, Czejka M: Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68:8-9, 1993
201. Bissett D, Kerr DJ, Cassidy J, et al: Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168-1171, 1991
202. Wilson WH, Jamis-Dow C, Bryant G, et al: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13:1985-1994, 1995
203. Thurlimann B, Kroger N, Greiner J, et al: Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol 121:R3-R6, 1995
204. Tolcher AW, Cowan KH, Solomon D, et al: Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer. J Clin Oncol 14:1173-1184, 1996
205. Bates SE, Wilson WH, Fojo AT, et al: Clinical reversal of multidrug resistance. Stem Cells 14:56-63, 1996
206. Bessho F, Kinumaki H, Kobayashi M, et al: Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med Pediatr Oncol 13:199-202, 1985
207. Philip PA, Joel S, Monkman SC, et al: A phase I study on the reversal of multidrug resistance (MDR) in vivo: Nifedipine plus etoposide. Br J Cancer 65:267-270, 1992
208. Linn SC, van Kalken CK, van Tellingen O, et al: Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 12:812-819, 1994
209. van Kalken CK, van der Hoeven JJ, de Jong J, et al: Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27:739-744, 1991
210. Scheulen ME, Meusers P, Schroder J, et al: Effect of dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high-dose cytosine arabinoside (Ara-C) in refractory acture myeloid leukemia (AML). Proc Am Soc Clin Oncol 12:308, 1993 (abstr)
211. Scheulen ME, Nubler V, Kriegmair M, et al: Phase I study of IV dexniguldipine plus vinblastine. Proc Am Soc Clin Oncol 13:156, 1994 (abstr)
212. Nuessler V, Scheulen ME, Oberneder R, et al: Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur J Med Res 2:55-61, 1997
213. Verweij J, Herweijer H, Oosterom R, et al: A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64:361-364, 1991
214. Rodenburg CJ, Nooter K, Herweijer H, et al: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2:305-306, 1991
215. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642, 1992
216. Samuels BL, Mick R, Vogelzang NJ, et al: Modulation of vinblastine resistance with cyclosporine: A phase I study. Clin Pharmacol Ther 54:421-429, 1993
217. Fisher G, Halsey J, Hausdorff J, et al: Phase I trial of taxol (T) with high-dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:144, 1994(abstr)
218. Warner E, Tobe SW, Andrulis IL, et al: Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 18:251-256, 1995
219. Chan HS, Koren CG, Thorner PS, et al: Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cycloporin A (CSA). Proc Am Soc Clin Oncol 11:375, 1992 (abstr)
220. Gallie BL, Budning A, DeBoer G, et al: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-1328, 1996
221. Hausdorff J, Fisher GA, Halsey J, et al: A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc Am Soc Clin Oncol 14:181, 1995 (abstr)
222. Collins HL, Fisher GA, Hausdorff J, et al: Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol 14:181, 1995 (abstr)
223. Fisher G, Halsey J, Hausdorff J, et al: A phase 1 study of paclitaxel (T) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR). Anticancer Drugs 5:43a, 1994 (abstr)
224. Giaccone G, Linn S, Catimel G, et al: Phase I and pharmacokinetic study of SDZ PSC 833 per OS in combination with doxorubicin in patients with solid tumors. Proc Am Soc Clin Oncol 13:142, 1994 (abstr)
225. Erlichman C, Moore M, Thiessen J, et al: A phase I trial of doxorubicin (D) and PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:134, 1994 (abstr)
226. Lemon S, Meadows B, Fojo A, et al: A phase I study of infusional vinblastine with the P-glycoprotein antagonist PSC 833 in patients with metastatic cancer. Proc Am Soc Clin Oncol 14:479, 1995 (abstr)
227. Boote DJ, Dennis IF, Twentyman PR, et al: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618, 1996
228. Stuart NS, Philip P, Harris AL, et al: High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br J Cancer 66:833-839, 1992
229. Trump DL, Smith DC, Ellis PG, et al: High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816, 1992
230. Millward MJ, Cantwell BM, Lien EA, et al: Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer :805-810, 1992
231. Millward MJ, Lien EA, Robinson A, et al: High-dose (480 mg/day) tamoxifen with etoposide: A study of a potential multi-drug resistance modulator. Oncology 51:79-83, 1994
232. Maenpaa J, Sipila P, Kangas L, et al: Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 46:292-297, 1992
233. Christen RD, McClay EF, Plaxe SC, et al: Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 11:2417-2426, 1993
234. Isonishi S, Kirmani S, Kim S, et al: Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. J Natl Cancer Inst 83:621-626, 1991
235. Budd GT, Bukowski RM, Lichtin A, et al: Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. Invest New Drugs 11:75-79, 1993
236. Jones RD, Kerr DJ, Harnett AN, et al: A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62:133-135, 1990
237. Wishart GC, Bissett D, Paul J, et al: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12:1771-1777, 1994
238. Rischin D, Webster LK, Millward MJ, et al: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88:1297-1301, 1996
239. Punt CJ, Voest EE, Tueni E, et al: Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 76:1376-1381, 1997
240. Figueredo A, Arnold A, Goodyear M, et al: Addition of verapamil and tamoxifen to the initial chemotherapy of small-cell lung cancer. A phase I/II study. Cancer 65:1895-1902, 1990